Table 1.
Baseline characteristics of participants and clinical fetures of breast cancer survivors
| Characteristics | Breast cancer survivors | Non-cancer controls | P-value |
|---|---|---|---|
| Age (yr) | 54.0±5.6 | 54.3±6.7 | 0.864 |
|
| |||
| Residence | 0.034 | ||
| Metropolitan | 22 (29.7) | 129 (43.6) | |
| Provincial | 52 (70.3) | 167 (56.4) | |
|
| |||
| Menopausal status | <0.001 | ||
| Premenopausal | 28 (37.8) | 75 (25.3) | |
| Postmenopausal | 44 (59.5) | 30 (10.1) | |
| Unknown | 2 (2.7) | 191 (64.5) | |
|
| |||
| Pregnancy | <0.001 | ||
| Ever | 57 (77.0) | 232 (78.4) | |
| Never | 7 (9.5) | 8 (2.7) | |
| Unknown | 10 (13.5) | 56 (18.9) | |
| Age of first pregnancy (yr) | 26.6±4.0 | 21.1±7.1 | <0.001 |
|
| |||
| Breastfeeding | 0.033 | ||
| Ever | 39 (70.9) | 164 (83.7) | |
| Never | 16 (29.1) | 32 (16.3) | |
|
| |||
| Body weight (kg) | 58.3±9.0 | 63.3±13.2 | 0.016 |
|
| |||
| BMI (kg/m2) | 23.7±3.8 | 26.0±5.5 | 0.003 |
|
| |||
| Family history of osteoporosis | 0.524 | ||
| Yes | 10 (14.3) | 19 (17.9) | |
| No | 60 (85.7) | 87 (82.1) | |
|
| |||
| Family history of fracture | |||
| Yes | 3 (4.2) | - | |
| No | 68 (95.8) | - | |
|
| |||
| Rheumatoid arthritis | 0.103 | ||
| Yes | 1 (1.4) | 15 (6.0) | |
| No | 73 (98.6) | 233 (94.0) | |
|
| |||
| Clinical information of breast cancer | |||
| Stage | - | ||
| I | 29 (39.7) | - | |
| II | 33 (45.2) | - | |
| III | 11 (15.1) | - | |
| Type of surgery | - | ||
| Total mastectomy | 21 (28.8) | - | |
| Partial mastectomy | 52 (71.2) | - | |
| Chemotherapy | - | ||
| Yes | 60 (82.2) | - | |
| No | 13 (17.8) | - | |
| HER-2 targeted treatment | - | ||
| Yes | 14 (18.9) | - | |
| No | 60 (81.1) | - | |
| Radiotherapy | - | ||
| Yes | 57 (77) | - | |
| No | 17 (23) | - | |
| Endocrine treatment | - | ||
| Yes | 69 (93.2) | - | |
| Tamoxifen | 58 (89.2) | - | |
| Aromatase inhibitor | 7 (10.8) | ||
| No | 5 (6.8) | - | |
|
| |||
| Total | 74 (100) | 296 (100) | |
Values are presented as mean±standard deviation or number (%).
BMI, body mass index; HER-2, human epidermal growth factor receptor 2.